Bristol Myers Squibb stock holds after recent earnings update

Bristol Myers Squibb (US0897961004) remains in focus as the latest available company data show 2025 revenue of $48.3 billion and full-year 2025 diluted EPS of $6.52. The company also reported a 2025 net income loss of $1.1 billion, while the investor-relations page remains the central source for the group’s latest filings and updates.

2025 revenue and EPS

The 2025 revenue figure of $48.3 billion and diluted EPS of $6.52 give investors a clear baseline for the stock’s valuation debate. The net income loss of $1.1 billion in 2025 adds a second layer, because earnings power and reported profit are not moving in lockstep.

That contrast matters for Bristol Myers Squibb stock, because the gap between revenue scale and bottom-line loss is what typically drives the market’s next read-through. A business generating tens of billions of dollars in annual sales can still face pressure if amortization, charges, or one-off items keep net income negative.

Loss versus scale

In 2025, the company’s reported loss of $1.1 billion stood against $48.3 billion in revenue, which is a useful comparison for judging operating quality. The ratio does not tell the whole story, but it does show that scale alone did not translate into positive reported profit over the period.

For Bristol Myers Squibb stock, that is the number pair that matters most right now: $48.3 billion of revenue and a $1.1 billion loss. The combination keeps attention on margin recovery, product mix, and the next reporting cycle rather than on headline sales alone.

Investor relations focus

The company’s investor-relations page is the live reference point for filings, earnings materials, and corporate disclosures. That matters because the latest evidence available here is report-based rather than event-driven, so the numbers themselves carry the story.

The current setup is therefore simple: a 2025 revenue base of $48.3 billion, diluted EPS of $6.52, and a reported net income loss of $1.1 billion. Those three metrics, all periodized to 2025, are the cleanest anchor for reading the stock without adding assumptions.

Opdivo and product mix

One representative product line is Opdivo, Bristol Myers Squibb’s flagship oncology therapy. It remains a central commercial reference point because oncology products continue to shape the company’s revenue mix and investor expectations.

For a stock like Bristol Myers Squibb, product concentration matters as much as the headline annual totals. The market typically looks for proof that a major brand can offset pressure elsewhere in the portfolio.

NYSE trading context

Bristol Myers Squibb stock trades on the NYSE, and the company’s scale makes it a large-cap pharma name rather than a speculative story. The latest quantified base in this article is the 2025 revenue figure of $48.3 billion, the 2025 diluted EPS of $6.52, and the 2025 net income loss of $1.1 billion.

The absence of a fresh, dated quote in the available evidence leaves the report metrics as the main anchor for the stock today.